33342-05-1 Usage
Uses
Used in Pharmaceutical Industry:
Gliquidone is used as a hypoglycemic agent for the treatment of non-insulin-dependent diabetes. It helps to lower blood glucose levels and improve the overall health of individuals with diabetes.
Used in Diabetes Management:
Gliquidone is used as an anti-diabetic agent for the treatment of hypoglycemia, which can lead to an increased risk of diabetic cardiovascular disease. It is also used in the treatment of diabetic nephropathy, a complication of diabetes that affects the kidneys.
Oral hypoglycemic agents
Gliquidone is an oral hypoglycemic agent, and was called as the second generation sulfonylurea oral hypoglycemic drug together with glyburide, gliclazide and glipizide, primarily for the treatment of non-insulin-dependent (namely, II type) diabetes. Its mechanism of action is the same as other sulfonylurea drugs and can stimulate insulin secretion from pancreatic β cells, and can enhance the action of insulin, enhance the sensitivity of tissues to insulin action, increase the number of insulin receptor and strengthen post-receptor action of insulin. During the early phase of treatment, it is mainly used for promoting the secretion of endogenous insulin; after a period of time of treatment, its main role is to improve the sensitivity of peripheral tissues to insulin. Diabetic nephropathy is one of the late complications of diabetes while gliquidone is the only sulfonylurea drugs that not affected by renal function and therefore can be applied to diabetic patients with impaired renal function. It is the primary-choice of drug for the treatment of patients of non-insulin dependent diabetes accompanied with insufficiency of renal function.
Gliquidone is characterized by short duration of action and seldom undergoing of renal excretion with a small dose being able to control postprandial blood glucose. Oral absorption is quick and complete. After the first oral administration of 30mg, the plasma concentration reaches its peak value, 500~700μg/L after 2 to 3 hours. The efficacy onset occurs at 1 hour after administration, the maximal effect can be extended up to 2 to 3 hours with the duration of 8 hours and the plasma protein binding rate being 99% and the half-life of about 1.5 hours. It is mainly metabolized in the liver through hydroxylation or demethylation with its metabolites having no significant hypoglycemic activity and most of them being discharged through feces via biliary while only 5% being subject to renal excretion. This product has mild effect and can be subject to dose adjustment timely based on blood sugar or urine glucose and rarely cause hypoglycemia reaction. It is suitable for the treatment of adult-type mild, moderate diabetes which can’t be simply treated through diet, especially for patients with renal insufficiency.
Diabetes
Diabetes is a group of syndrome of carbohydrate, fat, water and electrolyte metabolic disorder caused by the interaction of genetic and environmental factors, absolute or relative lack of insulin, and reduced cellular insulin sensitivity. According to the suggestion of ADA (in 1997) and WHO (in 1999), the diabetes are divided into four types, namely type 1 diabetes, type 2 diabetes, other specific types, and gestational diabetes. The vast majority belongs to type 2 diabetes (non-insulin-dependent diabetes mellitus, NIDDM), type 1 diabetes (insulin-dependent, IDDM) accounted for only 10% to 15%. The main clinical manifestations: polydipsia, polyphagia, polyuria, weight loss, fatigue, etc., advanced case is often accompanied with cataracts, abnormal reflexes in depth of feeling, urinary retention and skin infections. Type 1 " three polys and one little " is more obvious and is susceptible; the majority of patients with type 2 have no typical performances and is mainly in the form of complications or complications. Common complication mainly includes diabetic ketoacidosis and diabetic nonketotic hyperosmotic syndrome.
The above information is edited by the lookchem of Dai Xiongfeng.
Medicine interactions
The hypoglycemic effect of gliquidone can be enhanced by salicylates, sulfonamides, phenylbutazone, anti-tuberculosis drugs, tetracyclines, monoamine oxidase inhibitors, β receptor blockers and cyclophosphamide.
Combination with chlorpromazine, sympathomimetic drugs, corticosteroids, thyroid hormones, oral contraceptives and niacin preparations can reduce the hypoglycemic effect of this product.
Side effects
This product can be well tolerated. There is rare case of hypoglycemia during the treatment. There are only individual cases of patients who get gastrointestinal symptoms and skin allergy. Rare symptoms also include rash, jaundice, liver damage, bone marrow suppression, neutropenia, thrombocytopenia psychosis.
Precautions
1. Only 5% of this product is excreted through the kidneys. Therefore, for patients of diabetes with mild to moderate renal insufficiency, it is significantly better to adopt gliquidone rather than other sulfonylurea drug. However, for patients of severe renal dysfunction, insulin is still appropriate. Patients of pregnancy and those who are allergic to sulfonylureas, patients of insulin-dependent diabetes mellitus, patients of pre-coma and coma of diabetes, diabetic patients with acidosis or ketosis should be banned.
2. Children and lactating women should apply with caution. During medication, elderly should start from small dose and gradually adjust the dose.
3. In case of hypoglycemia reaction, the patients should immediately have carbohydrates diet. If hypoglycemia continues, the patients should consider discontinuing.
Originator
Glurenorm,Thornae,W. Germany,1975
Manufacturing Process
A mixture consisting of 4 grams of 1,2,3,4-tetrahydro-4,4-dimethyl-7-
methoxy-isochromanedione-(1,3) (MP 95° to 97°C), 2.53 grams of 4-
aminosulfonyl-phenyl-(2)-ethylamine and 150 ml of xylene was heated for 2
hours at its boiling point in an apparatus provided with a water separator.
Thereafter, the reaction mixture was allowed to cool and was then vacuumfiltered, and the filter cake was recrystallized from n-propanol in the presence
of activated charcoal. 2.9 grams (58% of theory) of 1,2,3,4-tetrahydro-4,4-
dimethyl-2-[p-aminosulfonylphenyl-(2)-ethyl]-7-methoxy-isoquinolinedione-
(1,3), MP 203° to 205°C, of the formula below were obtained.32.2 grams of 1,2,3,4-tetrahydro-4,4-dimethyl-2-[p-aminosulfonylphenyl-(2)-ethyl]-7-methoxy-isoquinolinedione-(1,3) were dissolved in 700 ml of
dimethylformamide, 9.1 grams of potassium tert-butylate were added to the
solution, and, while cooling the mixture with ice, 14.9 grams of cyclohexyl
isocyanate were added dropwise thereto.
Subsequently, the reaction mixture was stirred for 5 hours on an ice bath and
was then allowed to stand overnight at -2°C. Thereafter, the reaction solution
was admixed with water, the precipitate formed thereby was separated by
vacuum-filtration, the filtrate was admixed with more water, and the aqueous
solution was acidified with 2N hydrochloric acid. A greasy substance
precipitated out which crystallized after a brief period of contact with boiling
methanol. 2.6 grams (85% of theory) of 1,2,3,4-tetrahydro-2-[p-(N'-
cyclohexyl-ureido-N-sulfonyl)-phenethyl]-4,4-dimethyl-7-methoxyisoquinolinedione-(1,3), MP 180° to 182°C, were obtained.
Therapeutic Function
Oral hypoglycemic
references
[1]. oca?a m, del pozo e, baeyens jm. gliquidone, an atp-dependent k+ channel antagonist, antagonizes morphine-induced hypermotility. eur j pharmacol, 1993, 239(1-3): 253-255.[2]. oca?a m, baeyens jm. role of atp-sensitive k+ channels in antinociception induced by r-pia, an adenosine a1 receptor agonist. naunyn schmiedebergs arch pharmacol, 1994, 350(1): 57-62.[3]. von nicolai h, brickl r, eschey h, et al. duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. arzneimittelforschung, 1997, 47(3): 247-252.[4]. tuerk tr, bandur s, nuernberger j, et al. gliquidone therapy of new-onset diabetes mellitus after kidney transplantation. clin nephrol, 2008, 70(1): 26-32.
Check Digit Verification of cas no
The CAS Registry Mumber 33342-05-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,3,3,4 and 2 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 33342-05:
(7*3)+(6*3)+(5*3)+(4*4)+(3*2)+(2*0)+(1*5)=81
81 % 10 = 1
So 33342-05-1 is a valid CAS Registry Number.
InChI:InChI=1/C27H33N3O6S/c1-27(2)23-14-11-20(36-3)17-22(23)24(31)30(25(27)32)16-15-18-9-12-21(13-10-18)37(34,35)29-26(33)28-19-7-5-4-6-8-19/h9-14,17,19H,4-8,15-16H2,1-3H3,(H2,28,29,33)
33342-05-1Relevant articles and documents
Gliquidone preparation method
-
Paragraph 0032-0054, (2017/08/27)
The invention discloses a gliquidone preparation method. According to the preparation method, isoquinoline and cyclohexyl isocyanate carry out condensation reactions in a solvent in the presence of an alkali to generate gliquidone. 2,5-dimethyl tetrahydrofuran is taken as the solvent, isoquinoline can be well dissolved in 2,5-dimethyl tetrahydrofuran, while gliquidone is difficult to dissolve in 2,5-dimethyl tetrahydrofuran; thus, only a little amount of water is needed in the post treatment, the generated wastewater is largely reduced; the used alkali is common inorganic alkalis such as anhydrous potassium carbonate, and the like, is nontoxic, and is easy to process. The boiling point of 2,5-dimethyl tetrahydrofuran is low, 2,5-dimethyl tetrahydrofuran is easy to recover, moreover, the system is not afraid of water, the solvent can be circularly used, the production cost is reduced, the refluxing temperature is adopted, the operation is easy, the reactions last for 6 hours, and the method is rapid and efficient.
Investigation on the acylation of heterocyclic alcoholate anions with O,O-dialkyl phosphorochloridothioate in water solvent
Ge, Xin,Qian, Chao,Chen, Xinzhi
supporting information, p. 739 - 744 (2013/07/25)
The acylation of some heterocyclic alcoholate anions with O,O-dialkyl phosphorochloridothioate has been investigated. Higher yields and fewer byproducts were achieved in water at 50 °C by employing an effective phase-transfer catalyst (PTC) (benzyl triethylammonium chloride [BTEAC]), acylation catalyst (AC) (4-dimethylaminopyridine), and surfactant (sodium dodecyl sulfate), under weakly basic (pH 9.5～10) conditions. This reaction can also be applied to synthesize other insecticides with excellent yields.
Polymerization of Multifunctional Azides, and Polymers Therefrom
-
, (2011/04/18)
Methods for preparing polymers from multifunctional azides and multifunctional azide-reactants are described in the present disclosure. Exemplary multifunctional azide-reactants include multifunctional alkynes and/or multifunctional α-phosphine esters. In certain embodiments, such polymers can be prepared in vivo. Such polymers can be useful in a wide variety of biomedical applications.
NOVEL MULTIMERIC MOLECULES, A PROCESS FOR PREPARING THE SAME AND THE USE THEREOF FOR MANUFACTURING MEDICINAL DRUGS
-
, (2010/06/16)
The invention relates to a compound of the formula (I): in which k and j are independently 0 or 1, Y is a macrocycle in which the cycle includes 9 to 36 carbon atoms and is functionalised by three amino functions and by a chain for attaching the spacer arm Z via an X bond, Rc is a binding pattern with a receptor of the TNF superfamily, X is a chemical function for binding the Y group to the space arm, and Z is a bi-, tri- or tetra-functional spacer arm.
Concerted rate-limiting proton transfer to sulfur with nucleophilic attack at phosphorus - A new proposed mechanism for hydrolytic decomposition of the P=S pesticide, Diazinon, in moderately acidic sulfuric acid media
Churchill, Doreen,Dust, Julian M.,Buncel, Erwin
, p. 421 - 431 (2008/03/14)
We report herein the first kinetic study of a P=S containing organophosphorus pesticide, Diazinon (1), in the moderately concentrated acid region. Product analyses (31P NMR) show that reaction occurs only at the P centre. The rate-acidity profile (kobs vs. molarity of H 2SO4) appears as a curve in which the initial slight downward trace (molarity = 1 to ca. 5) is followed by sharper upward curve (molarity ca. 5 to 14). Using treatments involving the excess acidity (X) method, the A-1 and A-2 mechanistic possibilities were found to be inoperative over the full acidity range. A novel mechanism is proposed for the higher acidity (X ca. 2-6) region. This mechanism involves proton transfer to P=S from hydronium ion with concomitant proton transfer from water, which effectively delivers hydroxide to the P centre in a variant of the A-SE2 process. A putative A-2 mechanism in this region is supplanted by the proposed A-S E2 variant where the cyclic array results in proton transfer being efficiently coupled with nucleophilic attack involving water. This constitutes the first report of rate-limiting proton transfer at the P=S functionality in acid hydrolysis of this class of organophosphorus neutroxins. A 600 000-fold acceleration in the decomposition of Diazinon is associated with the change of medium from neutral aqueous solution to the most acidic medium studied (X ca. 6).
Cis-Alkoxyspiro-Substituted Tetramic Acid Derivatives
-
, (2008/06/13)
The invention relates to novel cis-alkoxyspiro-substituted tetramic acid derivatives of the formula (I), in which A, G, X, Y and Z are as defined above, to a plurality of processes and intermediates for their preparation and to their use as pesticides and/or herbicides, and also to selective herbicidal compositions comprising firstly cis-alkoxyspiro-substituted tetramic acid derivatives and secondly a crop plant compatibility-improving compound.
SUBSTITUTED SPIROCYCLIC KETOENOLS
-
, (2008/06/13)
The present invention relates to novel substituted spirocyclic ketoenols of the formula (I) in which W, X, Y, Z, A, B, D and G are as defined in the disclosure, to a plurality of processes for their preparation and to their use as pesticides, microbicides and herbicides.
Complexation of diazinon, an organophosphorus pesticide, with α-, β-, and γ-cyclodextrin - NMR and computational studies
Churchill, Doreen,Cheung, Jason Chiu Fung,Park, Yong Sung,Smith, Vedene H.,VanLoon, Gary,Buncel, Erwin
, p. 702 - 708 (2007/10/03)
Complexation of the organophosphorus pesticide, diazinon, with α-, β- and γ- cyclodextrin has been investigated through NMR and computational methodologies. Binding constants (Kb) determined by 1H and 31P NMR follow the order γ-CD > α-CD = β-CD, in contrast with reported Kb data for other pesticides and thus indicative of steric encumbrance by the isopropyl group in diazinon being an important factor influencing binding constants. The interaction of diazinon with the CDs has also been investigated through computational studies via molecular dynamics - molecular mechanics (MD-MM2) and density functional theory (DFT), B3LYP/6-31G*. It is shown that the most favorable orientation in binding corresponds to the hydrophobic heterocyclic residue of diazinon being pulled deepest into the CD cavity, in agreement with the experimentally determined order of binding constants. Moreover, the computations show that it is only with γ-CD that the heterocyclic residue of diazinon and the phosphoryl residue are both largely encrypted in the CD cavity, marking a clear differentiation with α-CD and β-CD where the phosphoryl residue is located largely outside the cavity. Thus, the computational results are in essential agreement with the experimental binding constants where γ-CD stands out with the highest Kb value. Our work could point to the potential usefulness of computational studies to be undertaken in tandem with experimental work in environmental situations such as soil remediation.
Aryl-substituted heterocyclic enaminones
-
, (2008/06/13)
The invention relates to novel heterocyclic enaminones of the general formula (I) in which Ar, Z, K, X, y1, Y2, Y3, Y4, Y5, Y6 and V are as defined in the description, to their use as herbicides, acaricides and insecticides, and to processes for their preparation.
Glyoxyl acid amides, method for producing them and their use for controlling harmful organisms
-
, (2008/06/13)
The invention relates to novel gloyoxylic acid amides, to a process for their preparation and to their use for controlling harmful organisms.
